Skip to main
SLP
SLP logo

Simulations Plus (SLP) Stock Forecast & Price Target

Simulations Plus (SLP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Simulations Plus Inc. demonstrates a positive outlook driven by its robust decade-long experience in utilizing data to enhance the accuracy of its pharmaceutical research software, which is expected to result in higher market growth than the overall industry. The company's anticipated margin expansion is particularly notable in its legacy biosimulation services, fueled by improved utilization rates, as staffing constitutes a significant portion of its expenses. Moreover, the increasing adoption of biosimulation in both preclinical and clinical programs is projected to bolster the company’s growth trajectory, with expectations for adjustments in EBITDA and EPS indicating operational strength and financial performance resilience.

Bears say

Simulations Plus has reported an adjusted EBITDA margin of 30.9% for the first three quarters of fiscal 2024, which is significantly below the company’s long-term average and its target of 35%-40%, indicating potential efficiency and profitability concerns. Key risks affecting the company's outlook over the next three to five years include a possible reduction in biotech funding, margin erosion due to an increased focus on service contracts over software sales, and challenges in attracting talent in a competitive environment. Additionally, projected revenue for fiscal 2025 has been slightly lowered to $91.3 million, highlighting the impact of anticipated diminished spending in the biotech and pharmaceutical sectors on Simulations Plus's near-term performance.

Simulations Plus (SLP) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Simulations Plus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Simulations Plus (SLP) Forecast

Analysts have given Simulations Plus (SLP) a Buy based on their latest research and market trends.

According to 6 analysts, Simulations Plus (SLP) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Simulations Plus (SLP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.